Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Mentari Therapeutics, Inc. Common Stock

MTRI

Mentari Therapeutics Inc is a biotechnology company engaged in the development of therapies for the prevention of migraine. Its product pipeline includes MT-001, an anti-PACAP monoclonal antibody, and MT-002, a bispecific antibody targeting both CGRP and PACAP pathways. The company's research and development activities focus on therapeutic candidates targeting PACAP and CGRP-related mechanisms for migraine prevention.

Last trade $17.73
Day change -$2.145 (-10.80%)
Day range $17.06 – $19.27
Volume 160,648
Market cap $1.16B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for MTRI.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for MTRI.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC

No recent company news found.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.